Introduction
P���-������������� ����f�������� �f ���� ������� p������� play a critical role in the regulation of gene expression (1) . A���������� �f ���� �������� b� ������� �����������f������ �� ���k�� �� ��������� �p����� ��� ��������p������ ���� ������-����; �� ��������, ������� ������������ (HDAC�) ������ ��� ������ ����p f��� �������� ��� ��p���� ���� ��������p���� (2) . HDACs regulate many important biological processes, ��������� ���� ����� p����������, ��ff����������� ��� ������p-ment (3) .
M��� ������� p��f����� �� ���� ���� ��p����� ����, �������� to adjacent normal mucosa, expression of HDAC1, HDAC2, HDAC3 ��� HDAC8, ����� ��� b����� �� ��� ����� I f����� of HDACs, is increased in colorectal carcinoma (4) (5) (6) (7) (8) (9) . Class I HDACs are frequently overexpressed in various human cancers, including colorectal cancer. Furthermore, their differential expression often correlates with drug resistance ��� p��� p��������, ����� ��k�� ���� �� ���������� ������ for cancer therapeutics (10, 11) . Studies have demonstrated a ���� f�� ����� I HDAC� �� p�������� ����� ���� p����f������� and survival (4, 7) . Knockdown of HDAC1, 2 and 3 reduces the ������ �f ������� ����� ������ ���� ����� ��������� HCT-116, HT-29 and SW-480 (4, 7, 12) . Mechanistically, the proliferative �ff���� �f HDAC� �� ����� ������ ����� ���� b��� ���k�� �� ��������p������ ��p������� �f ��� ������-��p������ k����� inhibitor, p21 (4, 12) . Knockdown of HDAC1, HDAC2 and HDAC3 induces p21 expression in colon cancer cell lines, while overexpression of these HDACs represses HDAC inhibitor-mediated p21 induction (13) .
R�������, HDAC ����b����� ���� �� ��b������������ hydroxamic acid (SAHA) and trichostatin A (TSA) have emerged as a promising class of therapeutic drugs. Crystallographic �������� ��� ����� ���� SAHA ��� TSA �������� �������� ���� ��� ��������� ���� �f �� HDAC-��k� p������ ��� ����b�� ��� enzymatic activity (14) . Inhibition of HDAC activity by SAHA and related agents alters gene expression, causing cell cycle ������ ��� �p�p����� �� ������ �����, p�������� b� ��� ��������� of p21 and Bax, a pro-apoptotic protein (15) . However, phase I ��� II ������� ���� ������������ ���� p��-HDAC ����b����� ��� ���� �������� ���� �ff����, ���� �� b��� ������ ��p���-����, ��������, ���������� �������� ��� ������� ����������� (16) (21) . In addition, the introduction of a normal ����� 1p36 ���������� f������� ���� ����� ������ ����� suppresses their tumorigenicity (22) . The RUNX3 gene is frequently inactivated through histone modification during ��� ������p���� �f ������� ����������, ��������� ������� ��� colon (20, (22) (23) (24) (25) (27) . A ���b�� �f ��p����� ���� b��� �������� f��� ������� and their possible antitumor activity has been extensively investigated in various cancer cell lines (28) (29) (30) . Among these ��p�����, 20-O-(β-D-glucopyranosyl)-20(S)-protopanaxadiol, or Compound K, is the main metabolite of protopanaxadiol-type �����������, f����� �� ��� ��������� �f��� ���� �������������� (31) (32) (33) . Our laboratory recently reported that Compound K exhibits cytotoxicity by inducing apoptosis, arrest of growth �� ��� G 1 p���� �f ��� ���� ����� ��� ����b����� �f ���������� activity in human leukemia cells (34, 35) . In addition, combined ��������� ���� C��p���� K ��� ����� ����������� �������� ��� ����� �f ����� ���� ������ ����� (36) ��� C��p���� K ������� �p�p����� �� MCF-7 b����� ������ ����� b� ���������� AMP-activated protein kinase (37) . In addition, we recently ������������ ���� C��p���� K ������� RUNX3 ������������ by DNA methyltransferase 1 inhibition (38) .
T�� ���� �f ���� ����� ���� �� ��������� ������� Compound K suppresses HDAC activity and expression and �� ��������� ��� ��������� ���������� b� ����� C��p���� K induces cell cycle arrest and apoptosis. The results demon-������ ���� C��p���� K ��� ������������ HDAC1, ������� �� ��� �������b����� �f ��� RUNX3 p������� ������ �� ���������� ������ HT-29 ����� ��� �������� �f ����������� �f �������� H3 and H4. Downregulation of HDACs represents a novel ��������� ���������� ��� �b����� �f C��p���� K �� ������ cell cycle arrest and apoptosis.
Materials and methods
Cell culture. H���� ���������� ������ HT-29 ����� ���� �b������ f��� ��� K����� C��� L��� B��k (S����, R�p�b��� �f Korea). Cells were maintained in an incubator at 37˚C with a humidified atmosphere of 5% CO 2 . The cells were cultured in RPMI-1640 medium containing 10% fetal calf serum, streptomycin (100 µg/ml) and penicillin (100 U/ml).
Cell proliferation assay. C��� p����f������� ��� ���������� using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cells were seeded into a 96-well plate at a density of 1x10 5 �����/�� ��� ���� ������� ���� 8, 16, 32 and 64 µmol/l of Compound K or TSA. After incubating for 48 h, 50 µl of the MTT stock solution (2 mg/ml) ��� ����� �� ���� ���� �� ������ � ����� �������� ������ �f 250 µl. After 4 h incubation, the supernatants were aspirated; the formazan crystals in each well were dissolved in 150 µl dimethylsulfoxide and absorbance at 540 nm was measured ����� � �������� �����-���� �p�����p��������� (TECAN, Melbourne, Australia).
Reverse transcription polymerase chain reaction (RT-PCR).
T���� RNA ��� �������� f��� ����� ����� TRIz�� ������� (Gibco BRL, Grand Island, NY, USA). Complementary DNA (cDNA) (1 µl) was amplified in a 25 µl reverse transcription reaction containing primers, dNTPs and 0.5 U of Taq DNA polymerase. The PCR conditions were 5 min at 94˚C for initial denaturation, followed by 35 cycles of 1 min at 94˚C, 1 min at 55˚C and 1 min at 72˚C and then a final elongation period of 7 min at 72˚C. PCR amplification was carried out in a Perkin-E���� C���� 9600 ������� ������ (R���� M�������� S������ Inc., NJ, USA). The primers used to amplify the RUNX3 and HDAC1 cDNA were as follows: RUNX3 sense, 5'-GGCAATG ACGAGAACTAC-3' (located in exon 2); RUNX3 antisense, 5'-GGAGAATGGGTTCAGTTC-3' (located in exon 5); HDAC1 sense, 5'-AACCTGCCTATGCTGATGCT-3'; HDAC1 antisense, 5'-CAGGCAATTCGTTTGTCAGA-3'; GAPDH sense, 5'-GTGGGCCGCCCTAGGCACCAGG-3'; and GAPDH antisense, 5'-GGAGGAAGAGGATGCGGCAGTG-3'. The amplified products were resolved on 1% agarose gels, which ���� ������� ���� �������� b������ ��� �������z�� ����� ����������� ����� ����� I����Q����™ TL �������� ��f����� (Amersham Bioscience, Uppsala, Sweden).
Methylation specific (MS)-PCR.
The bisulfate modification �f DNA ��� ������� ��� ���� ��� M�������p™ DNA ����-fication kit (Epigentek, Pittsburgh, PA, USA) according to the manufacturer's instructions. For analysis of DNA methyla-���� �f RUNX3, MS-PCR ������� ��� ����� �� Ep����� MSP kit (Qiagen, Valencia, CA, USA). The PCR products were separated on 6% non-denaturing polyacrylamide gels, stained with ethidium bromide and visualized under UV light. The ���������� �� ������������ RUNX3 p����� ��� �� �� f������: 5'-TTATGAGGGGTGGTTGTATGTGGG-3' and 5'-AAA ACAACCAACACAAACACCTCC-3' for unmethylated RUNX3; 5'-TTACGAGGGGCGGTCGTACGCGGG-3' and 5'-AAAACGACCGACGCGAACGCCTCC-3' for methylated RUNX3.
Western blot analysis. C���� ���� ��������� ��� ����� �� ice in 1 ml of lysis buffer (10 mmol/l Tris-HCl, pH 7.9, 10 ����/� N�C�, 3 ����/� M�C� 2 and 1% NP-40) for 4 min. Af��� ������f������� f�� 10 ��� �� 3,000 �, ��� p������ ���� re-suspended in 50 µl of extraction buffer (20 mmol/l HEPES, pH 7.9, 20% glycerol, 1.5 mmol/l MgCl 2 , 0.2 mmol/l EDTA, 1 ����/� DTT ��� 1 ����/� PMSF) ��� ���� ����b���� �� ��� for 30 min and centrifuged at 13,000 g for 5 min. The protein ������������� ��� �������� ��� ��p��������� ���� ������ �� -70˚C. Aliquots of the lysates (40 µg of protein) were boiled for 5 min and electrophoresed on a 10% SDS-polyacrylamide gel. Proteins were transferred onto nitrocellulose membranes, which were subsequently incubated with primary antibodies. T�� ���b����� ���� f������ ����b���� ���� ��������� ����-noglobulin-G-horseradish peroxidase conjugates (Pierce, Rockford, IL, USA). Protein bands were detected using an �������� ����������������� ������� b������� ��������� k�� (A�������, L����� C���f���, UK) ��� ���� �������z�� ����� � ����������� ����� �����z�� (BMG L�b����, Off��b���, Germany).
HDAC activity. Nuclear extracts were prepared using a nuclear protein extraction kit (Cayman Chemical, Ann Arbour, MI, USA). After measuring the protein concentration, the nuclear fractions were stored at -70˚C. HDAC activity was measured ����� �� Ep�Q��k HDAC �������� ����� k�� (Ep������k, Brooklyn, NY, USA), according to the manufacturer's instructions. In brief, the nuclear extracts were incubated with a specific substrate for 1 h at 37˚C, followed by capture antibody f�� 60 ��� ��� ���� ��������� ����b��� f�� 30 ��� �� ���� temperature. Absorbance at 450 nm was measured using a microplate spectrophotometer (TECAN). HDAC activity was ���������� �� ��/�/�� = {[�p����� ������� (�������-b���k)-optical density (sample-blank)] / Slope x h} x sample dilution.
Immunocytochemistry. Cells plated onto coverslips were fixed with 4% paraformaldehyde for 30 min and permeabilized with 0.1% Triton X-100 in PBS for 15 min. Cells were treated with blocking medium (3% bovine serum albumin in PBS) f�� 1 � ��� ���� ����b���� f�� 2 � ���� ��� RUNX3 ����b��� in blocking medium. The primary acetylated histone H3, ���������� ������� H4 ��� RUNX3 ����b����� ���� �������� by a FITC-conjugated secondary antibody (1:500; Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 h. After washing ���� PBS, ������� ����� ���� ������� ���� ��������p� ������ �� �������� ������ ���� DAPI (V�����, B���������, CA, USA) and imaged using the LSM 510 program on a Zeiss confocal microscope (Carl Zeiss Microscopy Ltd., Cambridge, UK).
Chromatin immunoprecipitation (ChIP) assay. T�� C�IP ����� ��� p��f����� ����� � S��p�� C�IP™ ��z������ ����-����� IP k�� (C��� S�������� T���������, D������, MA, USA), according to the manufacturer's protocol with slight modifications. Briefly, cells were treated with 20 µg/ml of Compound K for 48 h and then cross-linked by the addition of 1% formaldehyde. Chromatin was prepared and digested with nuclease for 12 min at 37˚C. ChIP was performed with the acetylated ������� H3, ���������� ������� H4 ��� RUNX3 ����b����� [C��� S�������� T��������� ��� Ab��� (C��b�����, UK)] ��� normal mouse IgG. Antibodies were added to the chromatin digests and were incubated with constant rotation at 4˚C overnight. ChIP-grade protein G magnetic beads were then added to capture the immune complexes. The beads were washed and the immunoprecipitates were eluted with ChIP elution buffer. The cross-links were reversed by incubation at 65˚C for 30 min. Proteinase K was added and incubated at 65˚C for 2 h. The immunoprecipitated DNA fragments were then purified using spin columns. DNA recovered from the immunoprecipitated complex was subjected to 35 cycles of PCR. The primers f�� ��� p21 (RUNX3 b������ ����) ��� RUNX3 (���������� H3, H4 b������ �����) ���� p�������� ���� �� f������: p21 �����, 5'-CACCAGACTTCTCTGAGCCCCAG-3'; p21 antisense, 5'-GCACTGTTAGAATGAGCCCCCTTTC-3'; RUNX3 sense, 5'-GGTTGCAGAAGTCACAGG-3'; and RUNX3 antisense, 5'-AATTTGCTTAGAACGTCCG-3'. The PCR products were separated on 2% agarose gels and DNA bands were visualized using the Image program (NIH, Bethesda, MD, USA). Statistical analysis. A�� ������������ ���� p��f����� �� ���p-licate and values are expressed as the mean ± standard error of the mean (SEM). The results were examined using analysis of variance (ANOVA) and Tukey's test to determine pairwise differences. P<0.05 was considered statistically significant.
Results

Compound K inhibits HDAC activity and expression in HT-29 cells.
W� �������� ������������ ���� C��p���� K ���� �� � DNA ����������f����� ����b���� �� ����� ���������� ������ ����� (38) ; ��� p������ ����� p������� �������� ���� C��p���� K also inhibits HDACs in human colorectal cancer HT-29 cells. C��p���� K ��� TSA ����b���� HT-29 ���� ������ �� � ����-��p������ ������ �� �������������� b������ 8 ��� 64 µ���/�; the concentration that yielded 50% growth inhibition (IC 50 ) was 32 µmol/l for Compound K and 24 µmol/l for TSA (Fig. 1) . A� � ������, 32 ��� 24 µ���/� ���� ������ �� ��� �p����� ����� of Compound K and TSA, respectively. Treatment of cells with ��� �p����� ���� �f C��p���� K ��������� HDAC1 �RNA and protein expression in a time-dependent manner ( Fig. 2A  and B) . HDAC enzyme activity was reduced at all time-points in ����� ������� ���� TSA ��� ��z��� �������� ��� ���� ��������� �� � ����-��p������ ������ �� ����� ������� ���� C��p���� K (Fig. 2C) .
Compound K increases histone acetylation. W� ���� �����-mined whether the decrease in HDAC expression and activity induced by Compound K affects histone acetylation. Compound K induced a significant increase in the acetylation of histones H3 and H4 in a time-dependent manner (Fig. 3A) . Furthermore, direct immunofluorescence analysis revealed ���� ���������� �������� H3 ��� H4 ��� p������ �� ��� ������ �f HT-29 cells following treatment with Compound K (Fig. 3B) .
Compound K reactivates RUNX3 via inhibition of HDAC.
T�� RUNX3 ���� �� HT-29 ����� �� ��p������� �p������������ silenced (39) (40) (41) (42) (43) . ChIP analysis revealed acetylation of the RUNX3 p������� �� C��p���� K-������� HT-29 ����� (Fig. 4A) , which resulted in the time-dependent re-expression of RUNX3 mRNA (Fig. 4B) and protein (Fig. 4C) . We ���� ������������ ������� ��� ������ �f DNA ����������� �� ��� RUNX3 p������� ������ ������� �f��� ��������� �f C��p���� K ��� �������� �� ����������� �f RUNX3 ���� expression. It was shown that unmethylation of the RUNX3 p������� ������ ������� �� HT-29 ����� b� ��������� �f Compound K, as well as TSA (Fig. 4D) . Mislocalization of ������� RUNX3 p������ �� ��� ����p���� ��� ���� �b������ �� HT-29 �����; �������, ��������� �f ����� ���� C��p���� K ��������� ��� ������� ������z����� �f ��� RUNX3 p������ (Fig. 4E) .
Compound K induces RUNX3-mediated expression of p21.
RUNX3 ���p������ ���� S���3 ��� S���4 �� �������� TGF-β-��p������ ������ ����b����� ��� ���� ������ �p�p����� b� inducing p21 and Bim (20, 41) . Enhanced p21 mRNA (Fig. 5A ) and protein (Fig. 5B ) expression was observed in HT-29 cells following Compound K treatment. Additionally, ChIP assay data showed that RUNX3 interacted with p21 (Fig. 5C) ; therefore, Compound K induced p21 expression via the binding of RUNX3 to the p21 promoter region.
Compound K induces cell cycle arrest and apoptosis. A������� of DNA content by flow cytometry revealed that Compound K ��� TSA ������ � ���k�� �������� �� ��� p��������� �f ����� �� ��� G 0 /G 1 phases of the cell cycle. Following Compound K ��������� �f HT-29 �����, ��� ���� p�p������� �� ��� G 0 /G 1 p���� at 6 and 12 h was 64 and 68% comparing to 50 and 52% cell p�p������� �� ��� G 0 /G 1 p���� �f ������� ����p; f�������� TSA treatment, 69% was in the G 0 /G 1 phase at 6 h and 37% �� ��� G 2 /M phase at 12 h compared to 50% in the G 0 /G 1 phase at 6 h and 21% in the G 2 /M p���� �� 12 � �f ������� group (Fig. 6A) . Furthermore, the sub-G 1 population (Fig. 6B ) and apoptotic body formation (Fig. 6C) were increased in Compound K-treated cells compared with control cells.
Discussion
Ep�������� ���� ���������� p���� � ������� ���� �� ��� �������� of cancer. Post-translational histone modifications are important epigenetic events in the regulation of gene expression and ����������� �f �������� f�������, ����� ��� ������b��� �� cancer development (44) (45) (46) . Abnormal histone modification �� � �������k �f ������ ���� �f��� ������ ��������� �f ����� ��pp������ �����, ����� �� ���� ����� �� ������ ������p���� and progression. The anti-carcinogenic effects and preventa-���� ������ �f C��p���� K, ��� ���� ����b����� �f ������� saponin, against colorectal cancer have been extensively studied in various tumor models (35) (36) (37) 47) ; however, less attention has been given to the epigenetic modifications induced b� C��p���� K ��� ����� p�������� ���� �� �������� ��� ���k of developing colorectal cancer. In this study, Compound K ������� ��� ��������p���� �f RUNX3 ��� p21 ��������p���� factors and reduced DNA methylation of RUNX3. Also, this C��p���� K ��������� ����������� �f �������� H3 ��� H4, leading to cell cycle arrest and apoptosis.
Class I HDACs are overexpressed in human colorectal cancer specimens and colorectal cancer cell lines (5,48) ; �p���f������, HDAC1, HDAC2 ��� HDAC3 ��� ������ expressed in colorectal cancer (11) . Overexpression of HDAC1 �� p������� ������ ����� ������ ��������� ���� p����f������� ��� � ��������� �� ���� ��ff����������� ���k���; HDAC1 ��� �����-fore represent a putative therapeutic target for cancer (49, 50) . HDAC� f��� �����-��b���� ��������p������ ��-��p������ complexes that are recruited to promoter regions by sequencespecific transcription factors (51) . There are reportedly several co-repressor complexes for distinct promoters, which recruit specific HDAC isoforms that silence their target genes. Class I HDACs are specifically responsible for deacetylation of the catalytic core of different co-repressor complexes, resulting in transcriptional repression. For example, HDAC1 and HDAC2 are present in the CoREST, mi2/NURD and Sin3 complexes ��� HDAC3 �� ���p����b�� f�� ��� ��������� ���������� �f ��� N-CoR and SRMT co-repressor complexes (51) . Silencing of RUNX3 b� HDAC� p���� �� ��p������ ���� �� ��� ���������� �f ����� ��pp������� ������ ������� ��� ����� �������������� (26, 27) .
I� �� ��p������ �� ���� ���� C��p���� K �ff���� HDAC1 ��� �����f��� ��� p��f���� �ff���� �� ������ �����; �������, ��� �p���f�� ���������� ���������� ����� �ff���� ��q����� f������ �����f�������, �p���f������ ���� ������ �� �����-�������� ��� ��ff�������� ���p���� �f ���������� ������ ����� �� Compound K. Repression of tumor suppressor genes involves ������������� �f ������� ��������p���� f������ b� ����� I HDAC� (32, 33) . In addition, evidence to date indicates that specific HDACs are consistently overexpressed in colon cancer. The effect of overexpression and depletion of multiple class I HDAC� �� ��� ������ ��� �������� �f ����� ������ ����� ��� b��� ������������ in vitro in a number of studies; for example, deficiency of HDAC1, 2 and 3 reduces the growth of several colon cancer cell lines (4, 7, 12) . In this study, we observed a ��ff�������� ���p���� �f C��p���� K-�������� ���� �����, probably due to significant inhibition of class I HDACs at the protein and mRNA levels. The results provide additional �������� ���� C��p���� K ����b��� ����� I HDAC� b� �������� the acetylated histone status and enhancing the expression of tumor suppressor genes and pro-apoptotic proteins. These �ff���� ���� �����p����� b� ������p������ ��������� �� ���� growth inhibition and apoptosis.
T���� ��pp������ ���� ��p������� �������� ������������� of various transcription factors by class I HDACs. Class I HDAC-�������� ������������� ��� b��� ����� �� �������� ��� DNA-b������ �������� �f ��q�����-�p���f�� ��������p-tion factors. For example, covalent modifications of several transcription factors, including E2F, SP1/ SP3, p53, GATA1, TFIIF ��� RUNX3 b� ����� I HDAC�, ���� b��� ��p����� (51) (52) (53) . HDAC inhibitors reduce HDAC activity, altering ��� ������� b������ b������ HDAC ��� ������� ������-�����f����� ��������, ����� ������� �� ��������� ����������� of non-histone proteins, including RUNX3. Deacetylation b� HDAC1 ��� HDAC2 ������� �� ��� ��������� �f RUNX3 ��� HDAC ����b����� ���� b��� ����� �� ������� ���� p������ (54, 55) . Inhibition of HDACs results in the acetylation of RUNX3, �����b� ���������� b��� ��� ���f-��f� ��� b������ �� the p21 promoter (54) . Our chromatin immunoprecipitation assays confirmed an increase in the expression of acetylated �������� H3 ��� H4 ���������� ���� ��� RUNX3 p������� �� the nuclei of HT-29 cells.
I� ����������, ���� ����� ������������ ���� C��p���� K ��� �������� HDAC ��z��� �������� ��� ��� b� �ff������ �� inhibiting cancer cell growth. The degree of HDAC inhibition and the alterations in downstream gene expression induced by C��p���� K ���� ������� �� ����� ������� b� TSA, � p�����-cological inhibitor of HDACs. Our data suggest that epigenetic ���������� �f ����� ��pp������ ����� b� C��p���� K ��� play a role in colorectal cancer chemoprevention or therapy. These findings are important for understanding the anticancer mechanisms and clinical applications of Compound K.
